Overview
McDermott health lawyers were cited for their analysis of a CMS proposed rule that “would impact a broad and diverse range of Medicare Advantage (MA) and Part D regulatory requirements, and would affect not only MAOs (MA organizations), but also health care providers, pharmacies, pharmaceutical manufacturers and others.”